Antiplatelet Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Antiplatelet Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

Antiplatelet drugs are agents that help reduce the ability of platelets to stick together, which is also known as platelet aggregation, thereby inhibiting blood clot formation. Antiplatelet agents are used to prevent and treat ischemic stroke (strokes caused by a blood clot), stent thrombosis, and myocardial infarction (heart attacks). Ischemic stroke is caused by blockage of flow of blood because of a clot in the vessels that supply blood to the brain. The brain does not get enough supply of oxygen and blood if the flow of blood is stopped for more than a few seconds. This causes permanent damage in the brain and the cells in the brain can die. The three major classes of antiplatelet drugs are glycoprotein platelet inhibitors, platelet aggregation inhibitors, and protease-activated receptor-1 antagonists. To prevent the adhesion of platelets, the glycoprotein platelet inhibitors bind to glycoprotein IIb/IIIa receptors of platelets on the plasma membrane. Thrombus is formed due to the sticking together of the platelets. The inhibition of formation of thrombus by the stopping the binding to the receptor prevents deep vein thrombosis, myocardial infarction, and stroke. Platelet aggregation inhibitors prevent formation of clot by inhibiting platelet adhesion in different places of the clotting cascade. The balance between thromboxane (which promotes aggregation) and prostacyclin (that inhibits platelet aggregation) is changed due to one of the commonly used antiplatelet drug, the aspirin. The irreversible inhibition of the enzyme cyclo-oxygenase leads to reduction in prostacyclin of vascular endothelial cells and thromboxane synthesis in platelets.

Increase in prevalence of ischemic stroke, stent thrombosis, and myocardial infarction across the world boosts demand for antiplatelet drugs. According to the American Heart Association, nearly 800,000 people have a stroke in the U.S. each year, and three in four people experience first-time strokes. Among these, 87% are ischemic strokes. According to the Centers for Disease Control and Prevention (CDC), about 735,000 people in North America and Latin America have a heart attack, among these 525,000 people experience heart attack for the first time.

The global antiplatelet drugs market can be segmented based on drug class, disease type, distribution channel, and region. In terms of drug class, the market can be classified into glycoprotein platelet inhibitors, platelet aggregation inhibitors, and protease-activated receptor-1 antagonists. Based on disease type, the market can be categorized into ischemic stroke, stent thrombosis, and myocardial infarction. Based on distribution channel, the market can be categorized into retail pharmacies, online pharmacies, and hospital pharmacies.

Geographically, the global antiplatelet drugs market can be classified into Asia Pacific, Latin America, Europe, Middle East & Africa, and North America. North America held the largest market share in 2016. The market in the region is anticipated to be driven by rise in number of patients suffering from myocardial infarction. Europe held the second largest market share in 2016, owing to increase in research and development on antiplatelet drugs. The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period due to increase in initiatives by governments in countries such as India and China to reduce deaths due to ischemic stroke, stent thrombosis, and myocardial infarction. The antiplatelet drugs market in Middle East & Africa and Latin America is likely to be driven by increase in prevalence of heart attacks.

Key players in the global antiplatelet drugs market include Merck & Co., Inc., Eli Lilly and Company, Sanofi, Bristol-Myers Squibb Company, Otsuka Pharmaceutical Company, Ltd., Daiichi Sankyo, Inc., Boehringer Ingelheim GmbH, AstraZeneca, and The Medicines Company.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis. 

Have query on this report?

Make an Enquiry

Success Stories

Our Clients